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Abstract
Progressive multifocal leukoencephalopathy (PML), a demyelinating disease of
the brain, is typically diagnosed in immunocompromised persons. Here, we
describe the diagnostic challenge of PML in an apparently immunocompetent
patient. Thorough analyses, including cytokine release assays and whole exome
sequencing, revealed a deficit in the antiviral interferon gamma production
capacity of this patient and compound heterozygous mutations in BCL-2-asso-
ciated athanogene 3. Interestingly, both factors are associated with reduced
expression of John Cunningham virus T-antigen, a protein that plays a key role
in viral replication in infected cells. After validation in other patients, our find-
ings may contribute to novel insights into the etiology and possibly treatment
of PML.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a
destructive demyelinating disease of the central nervous
system caused by the John Cunningham virus (JCV),
which belongs to the family of polyoma viruses. The
onset of the disease is subacute, with a broad range of
clinical features. Its course is progressive and often fatal.1
Carriership of JCV is common among healthy individuals
and it remains latent in the kidney, lymphoreticular, or
brain tissue. Approximately 70% of adults are seropositive
for JCV. Reactivation of the virus, resulting in PML,
occurs typically under immunosuppressive conditions.1
The growing number of immunosuppressive and
immunomodulatory therapeutics has resulted into an
increased number of individuals at risk for PML.2
Although the common denominator in all these condi-
tions is suppression of cellular immunity (either iatro-
genic or endogenous), PML may also occur in patients
with minimal or occult immune suppression (e.g., idio-
pathic CD4+ lymphocytopenia, chronic kidney, or liver
disease)3 and even occasionally in apparently immuno-
competent patients.4 Here, we present a case of PML in
an apparently immunocompetent patient in whom a
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deficit of the interferon c (IFNc) pathway, and compound
heterozygozity for mutations in BCL2-associated athano-
gene 3 (BAG3) were identified.
Patient and Methods
A 49-year-old Caucasian male presented with rapidly pro-
gressive symptoms of aphasia, dyscalculia, hyperesthesia
of the right arm, and headache. Two months after the
first symptoms, his clinical condition worsened acutely
with an inability to speak and to carry out activities of
daily living, apraxia, confusion, and severe headache. His
vital signs were normal and neurologic examination con-
firmed a nonfluent aphasia, dysgraphia, mild facial paresis
on the right, a right-sided hemianopsia, hemi-hypaesthe-
sia, and hyperreflexia without extensor plantar responses.
He used no medication and had no significant medical
history. The family history was unremarkable for neuro-
logic conditions. Laboratory tests showed normal leuko-
cyte counts, including CD3, CD4, and CD8 counts (ratio
T4/T8), low infectious parameters, negative serology for
human immunodeficiency virus (HIV), Lues, Borrelia,
and Herpes Simplex Virus (HSV). Cerebrospinal fluid
(CSF) analysis showed normal cell counts, protein and
glucose levels, no oligoclonal bands or markers of neu-
rodegeneration (except for a slightly elevated Tau
[431 ng/L], normal <300 ng/L), and cytological analysis
showed no signs of malignancy. Cerebral MRI showed
confluating subcortical white matter T2 hyperintensities
predominantly in the left hemisphere, which extended on
consecutive MRIs without contrast enhancement or mass
effect (Fig. 1). PCR for JCV in serum and CSF was nega-
tive.
A stereotactic biopsy of the left frontal lobe showed
perivascular lymphocytic infiltration with sporadic
enlarged nuclei, which resembled astrocytes. No patho-
logic oligodendrocyte nuclei were found and immunohis-
tochemical staining for SV-40 (polyomavirus) was
negative. However, a positive PCR alone is no confirma-
tion of active virus replication. The PCR for JCV on the
biopsy material, however, was positive. The normal
immune status and the lack of evidence for an active JCV
infection led to the primary diagnosis of tumefactive mul-
tiple sclerosis, and the patient was treated consecutively
with methylprednisolone intravenously, glatiramer acetate
(20 mg/mL once daily), acetaminophen (1000 mg four
Figure 1. MRI images 4 months after first presentation. (A) Fluid-attenuated inversion recovery (FLAIR) MRI: large confluating asymmetric white
matter hyperintensities lesions in the frontal and parietal lobes. (B) T1-gadolinium sequences without contract enhancement.
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times a day), and plasmapheresis.5 As deterioration con-
tinued the biopsy material was re-examined 7 months
after symptom onset, in a tertiary center with extensive
expertise on PML. The presence of foam cells, some
bizarre astrocytes, and sporadic oligodendrocytes with
ground glass appearance combined with the clinical
course led to a revision of the diagnosis to PML, and the
patient was started on mirtazapine (15 mg once daily).
Unfortunately his condition was progressive and he died
9 months after the initial presentation due to cardiopul-
monary complications of a bilateral pneumonia. Autopsy
confirmed the diagnosis of PML. Macroscopy showed
extensive white matter hyperintensities in both hemi-
spheres, with focal gray glass lesions, suggestive for PML.
Microscopy showed large white matter hyperintensities
with prominent demyelination, and a granular tissue loss.
Extensive reactive astrocytosis, and astrocytes with
enlarged polymorph hyperchromatic nuclei were found,
indicating a viral cytopathogenic effect. A few oligoden-
drocytes with enlarged nuclei, perivascular foamy macro-
phages, and some lymphocytic infiltration were seen.
Immunological assessment
After the diagnosis of PML an assessment of the capacity of
cells isolated from the patient to respond to microbial stim-
uli was initiated. Peripheral blood mononuclear cells were
isolated from blood collected from the patient, and stimu-
lated with the TLR4-ligand lipopolysaccharide (Escherichia
coli LPS 10 ng/mL), the TLR3-ligand PolyI:C (5 lg/mL),
and a fungal stimulus (heat-killed Candida albicans 105
microorganisms/mL). IFNc production capacity was mea-
sured using an enzyme-linked immunosorbent assay.
Genetic analysis
Whole exome sequencing was performed as described ear-
lier.6,7 In brief, DNA was isolated from whole blood,
enriched with SureSelect v2 exome (Agilent Technologies,
Santa Clara, CA) (50 Mb) and sequenced on SOLiD 4
(Life Technologies, Foster City, CA). Variants were called
using high stringency settings and annotated with an in-
house pipeline containing information from dbSNP134.
Variant filtering was applied as previously reported; in
brief, we only selected variants affecting coding exons,
microRNAs, and canonical splice sites. Subsequently, syn-
onymous variants were filtered out, and only rare variants
(frequency of <0.25% in both dbSNP134 and our in-
house database containing >2000 exomes) with high qual-
ity were reported (Table 1). All genes with rare nonsyn-
onymous variants were systematically checked for
involvement role in immunity; based on Gene Ontology
terms, mouse knockout phenotypes, information from the
Kyoto Encyclopedia of Genes and Genomes or direct
interaction with JCV according to NCBI (the latter was
performed by searching for JCV in NCBI, and selecting
for genes in humans).
Table 1. Exome sequencing statistics and the filter settings applied to
exclude noncoding, nonsynonymous, common, and low-quality variants.
Sample PML patient
Total mapped bases (Gb) 5.5
On and near target (%) 82.0%
Median fold coverage 57.6
Average fold coverage 81.7
% Covered >onefold 94.1%
% Covered >10-fold 82.8%
% Covered >20-fold 74.5%
Total variants 35,322
Coding, canonical, microRNA 14,595
Nonsynonymous 7211
Rare variants <0.25% SNP, in-house exomes 188
Variant reads >5% and >25% 106
Variants in immune-related pathways 21
Associated with JCV (NCBI) 2 variants,
1 gene (BAG3)
PML, progressive multifocal leukoencephalopathy; BAG3, BCL2-asso-
ciated athanogene 3; JCV, John Cunningham virus.
Figure 2. Interferon c (IFNc) production capacity was measured in the
progressive multifocal leukoencephalopathy (PML) patient and
compared with eight healthy controls upon stimulation with the TLR3
ligand PolyI:C (5 lg/mL) (left) and Candida albicans (1 9 105
microorganisms/mL) (right). The PML patient showed a clear defect in
IFNc production upon PolyI:C stimulation compared to controls,
whereas stimulation with Candida does not result in significant
differences.
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Results
Immunological assessment
While cytokine production upon stimulation with LPS
and C. albicans was normal compared to eight healthy
individuals. IFNc production induced by PolyI:C was
severely impaired in the patient versus control stimulation
(Fig. 2). We were unable to perform extensive
immunophenotyping of T-, B-, and NK-cell subpopula-
tions as our patient deceased shortly after the diagnosis of
PML.
Genetic analysis
Whole exome sequencing provided 5.5 Gb of mapped
sequencing data, resulting in an average coverage of the
exome of 81.7-fold. Standard variant filtering resulted in
106 rare, nonsynonymous, and canonical splice site vari-
ants. Only 17 genetic variants remained after filtering for
genes with a possible role in immunity (Table 2). A gen-
ome-wide search in NCBI for genes associated with JCV
interaction resulted in 21 genes. An overlap between these
21 genes, and the 106 rare variants resulted in one gene
for which JCV interaction was described earlier8,9; we
found two very rare heterozygous variants in exon 2 of
the BAG3. Cosegregation analysis within the family shows
that both unaffected parents carry one of the variants in a
heterozygous state, and both variants are absent in the
healthy brother (Fig. 3). The variants (p. P77L; p.I94F)
have been reported at population allele frequencies of
0.029% and 0.076%, respectively. In addition, rare (<1%)
homozygous protein-altering variants are only reported in
16 of >60,000 controls.10
Discussion
Although rare, similar cases of PML in apparently
immunocompetent individuals have been reported.4,11,12
Due to its variable demographics, presenting symptoms,
and prognosis, the diagnosis of PML remains a challenge,
especially in apparently immunocompetent individuals.
The diagnosis can be strengthened by a positive PCR for
JCV in the CSF, which has a high sensitivity and speci-
ficity. However, the severity of the immunosuppression
seems to determine the accuracy of the available tests, as
is illustrated by the low JCV DNA copy numbers in the
CSF of highly active anti-retroviral therapy treated
(HAART) HIV patients, as well as in nearly half of the
multiple sclerosis patients treated with the monoclonal
antibody natalizumab who were diagnosed with PML.13–
15 Moreover, JCV PCR in CSF of PML cases with occult,
minimal, or no detected immune suppression was often
found negative.4 Also, substantial variability exists with
Figure 3. Family pedigree of our progressive multifocal leukoencephalopathy (PML) case; the unaffected parents were both carrier of one rare
BCL2-associated athanogene 3 (BAG3) variant (paternal variant p.P77L, c.230C>T; maternal variants p.I94F, c.280A>T). The compound
heterozygosity for these BAG3 variants most likely affects the resistance against John Cunningham virus (JCV) in the index patient. Neither of the
two variants is present in the unaffected brother.
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regard to detection levels and consistency between labora-
tories even in testing the same sample set. If clinical sus-
picion remains high and JCV PCR in CSF is negative, a
brain biopsy should therefore be performed. It is impor-
tant to realize that JCV DNA is widespread in the brain
of healthy adults and that the viral DNA load seems to
increase in immunosuppresive conditions, as was
observed in an autopsy study in HIV patients without
PML (no clinical symptoms during life and no
neuropathologic evidence of PML).16 Expression of viral
proteins, which can be demonstrated by immunohisto-
chemistry is, however, considered a pathognomonic sign
of PML. In our case, viral DNA was found in the biopsy
material, however, expression of viral proteins was not
observed. Therefore, PML was initially not considered the
most likely diagnosis in this immunocompetent patient.
Identifying factors that determine JCV reactivation in an
immunocompetent patient will profoundly contribute to
the understanding of pathogenesis of PML.17 Moreover, it
might contribute to novel treatment options. IFNc is an
important cytokine in human antiviral cellular immune
response. The observation that the IFNc response in our
patient was decreased after stimulation with PolyI:C, a syn-
thetic TLR3 ligand used to simulate viral infections, suggests
a specific deficit in the cellular antiviral immune response.
Interestingly, IFNc was recently reported to inhibit expres-
sion of JCV T-antigen, the major viral regulatory protein.18
In addition, this study showed a significant decrease of JCV
DNA copies in cells upon IFNc treatment in vitro. The
observed IFNc deficit is most likely an important factor in
the pathogenesis of PML in our patient; whole exome
sequencing was performed in order to identify any genetic
defects that could contribute to this deficit. Compound
heterozygous BAG3 variants in our patient are worthy can-
didates for increased susceptibility to PML as BAG3 is impli-
cated in autophagy and apoptosis through intracellular
protein control. It was previously shown that overexpression
of BAG3 results in a decrease of the JCV replication, and
reduced T-antigen expression through autophagic degrada-
tion, thereby controlling the JCV lytic cycle and its interac-
tion with host cells.9 Although it remains speculative, the
observed genetic variants in BAG3 might compromise the
response against JCV T-antigen in our patient, leading to
insufficient IFNc production, and subsequently PML.
Obviously this case report has several limitations and
the results should be interpreted with caution. First,
although the segregation analysis showed an autosomal
recessive inheritance, the family is rather small, which
makes the pathogenicity uncertain. Validating our find-
ings in other cases is therefore crucial, however, due to
the rarity of PML in apparent immunocompetent patients
this remains extremely challenging. We took up this chal-
lenge and performed genetic testing for BAG3 variants in
two previously reported apparent immunocompetent
PML cases.11,12 Unfortunately, no BAG3 variants were
discovered in these patients. Given the number of factors
suggested to be involved in the reactivation of JCV in
order to develop PML and therefore increased hetero-
geneity between these patients, this might not be surpris-
ing.17,19 In addition to the genetic variants in BAG3, we
also provide evidence for low INFc levels in this case.
However, a possible association between the IFNc deficit
and the BAG3 variants remains to be shown.
This case report shows that specific defects in the IFNc
production upon stimulation may be present in PML
patients without known immune deficits. Patients sus-
pected of PML without immunosuppression should, in
addition to regular immunologic screening, be tested for
IFNc deficiency to confirm our findings. In these condi-
tions treatment with IFNc might potentially be an option
for PML, similar to other conditions treated with recombi-
nant IFNc.20
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